These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16311686)

  • 1. Prescribing pattern of angiotensin- converting enzyme inhibitors and beta blockers after acute myocardial infarction.
    Sweileh WM; Shkokani FM; Sawalha AF; Al-Ramahi RJ; Jaradat NA; Zaid AA; Barakat AS
    Saudi Med J; 2005 Nov; 26(11):1837-9. PubMed ID: 16311686
    [No Abstract]   [Full Text] [Related]  

  • 2. Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002.
    Gislason GH; Abildstrom SZ; Rasmussen JN; Rasmussen S; Buch P; Gustafsson I; Friberg J; Gadsbøll N; Køber L; Stender S; Madsen M; Torp-Pedersen C
    Scand Cardiovasc J; 2005 Apr; 39(1-2):42-9. PubMed ID: 16097413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
    Kizer JR; Cannon CP; McCabe CH; Mueller HS; Schweiger MJ; Davis VG; Perritt R; Antman EM
    Am Heart J; 1999 Jan; 137(1):79-92. PubMed ID: 9878939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines and registries: secondary prophylaxis after AMI with emphasis on the use of beta-blockers and ACE inhibitors.
    Otterstad JE
    Scand Cardiovasc J; 2005 Apr; 39(1-2):10-2. PubMed ID: 16097408
    [No Abstract]   [Full Text] [Related]  

  • 10. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.
    Pilote L; Beck CA; Karp I; Alter D; Austin P; Cox J; Humphries K; Jackevicius C; Richard H; Tu JV;
    Can J Cardiol; 2004 Jan; 20(1):61-7. PubMed ID: 14968144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with acute myocardial infarction and end-stage renal disease.
    Conti CR
    J Am Coll Cardiol; 2003 Jul; 42(2):209-10. PubMed ID: 12875752
    [No Abstract]   [Full Text] [Related]  

  • 13. [Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
    Coma-Canella I
    Rev Esp Cardiol; 2006 Mar; 59(3):189-92. PubMed ID: 16712740
    [No Abstract]   [Full Text] [Related]  

  • 14. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
    Austin PC; Tu JV; Ko DT; Alter DA
    CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
    Björck L; Wallentin L; Stenestrand U; Lappas G; Rosengren A
    Arch Intern Med; 2010 Aug; 170(15):1375-81. PubMed ID: 20696964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
    Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry.
    Danchin N; Blanchard D; Steg PG; Sauval P; Hanania G; Goldstein P; Cambou JP; Guéret P; Vaur L; Boutalbi Y; Genès N; Lablanche JM;
    Circulation; 2004 Oct; 110(14):1909-15. PubMed ID: 15451803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary prevention after an acute myocardial infarct. Adrenergic beta-blockers, angiotensin-converting enzyme inhibitors and statins for everyone?].
    Morais J
    Rev Port Cardiol; 2000 Jan; 19(1):99-105. PubMed ID: 10731795
    [No Abstract]   [Full Text] [Related]  

  • 20. Time trends in the treatment of acute myocardial infarction in Switzerland from 1986 to 1993: do they reflect the advances in scientific evidence from clinical trials?
    Bourquin MG; Wietlisbach V; Rickenbach M; Perret F; Paccaud F
    J Clin Epidemiol; 1998 Sep; 51(9):723-32. PubMed ID: 9731920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.